OakChart

Spruce Biosciences Inc

SPRBHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

46.20-0.47 (-1.00%)
2026-11-11 23:40 CET
Market cap
134.12 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-67.15 USD m
Free cash flow, TTM
-51.21 USD m
EPS diluted, TTM
-34.80
P/E
-
Compare

Price

SPRB against its 20, 50 and 200-day averages
2050200miss
40.0050.0060.0070.00212K423KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SPRBclose 46.2020-day 44.6050-day 47.85200-day 54.4446.2052w low

63.9% under the 52-week high of 127.90 on 19 Nov 2025. 52-week low 38.06 on 14 Oct 2026. Last 15 sessions, 25.1% high to low

Volume 0.59× normal · the line is the 50-bar volume average

Profile

SPRB
52-week range, 9% of the way up
38.06127.9

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

IndexRUT
Employees8
IPOOct 09, 2020
Beta3.55
ATR, 14d3.52
Rel volume0.59
Short float21.17%
Insider own12.62%
Inst own66.73%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap132.78M
Enterprise Value53.41M
Income-67.15M
Sales0.00M
Book/sh23.07
Cash/sh30.51
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOOct 09, 2020

Ratios

P/E-
Forward P/E28.56
PEG0.69
P/S-
P/B2.00
P/C1.51
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.83
Current Ratio4.83
Debt/Eq0.13
LT Debt/Eq0.06
Option/ShortNo / Yes

Earnings

EPS (ttm)-34.80
EPS next Y1.62
EPS next Q-5.94
EPS this Y44.84%
EPS next Y105.77%
EPS next 5Y41.22%
EPS past 3/5Y29.85% 11.80%
Sales past 3/5Y- -
EPS Y/Y TTM58.95%
Sales Y/Y TTM-100.00%
EPS Q/Q41.66%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.-49.94% -

Ownership

Insider Own12.62%
Insider Trans0.00%
Inst Own66.73%
Inst Trans37.64%
ROA-125.20%
ROE-187.35%
ROIC-95.55%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.60%
SMA50-3.44%
SMA200-15.14%
Trades-

Technical

Shs Outstand2.87M
Shs Float2.51M
Short Float21.17%
Short Ratio6.22
Short Interest0.53M
52W High127.90 -63.88%
52W Low38.06 21.39%
Volatility11.60% 7.57%
ATR (14)3.52
RSI (14)50.90
Beta3.55
Rel Volume0.59
Avg Volume85.44K
Volume50,247

Performance

Perf Week-0.88%
Perf Month14.50%
Perf Quarter-7.17%
Perf Half Y-19.72%
Perf YTD-46.96%
Perf Year-58.99%
Perf 3Y-41.33%
Perf 5Y-86.00%
Perf 10Y-
Recom1.00
Target Price147.89
Prev Close46.67
Price46.20
Change %-1.00%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedLLake StreetBuy$149+222.5%
Jul 13, 2026InitiatedRB. Riley SecuritiesBuy$160+246.3%
Jun 16, 2026InitiatedGGuggenheimBuy$123+166.2%
Apr 27, 2026InitiatedCCraig HallumBuy$140+203.0%
Dec 23, 2025InitiatedOOppenheimerOutperform$283+512.6%
Dec 03, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$160+246.3%
Oct 28, 2025UpgradeCCitizens JMPMkt Perform → Mkt Outperform$254+449.8%

Peers

Mkt cap
TickerCompanyMkt cap
RAREUltragenyx Pharmaceutical Inc1.70B
DNLIDenali Therapeutics Inc3.16B
RGNXRegenxbio Inc560.06M
BMRNBiomarin Pharmaceutical Inc11.30B
PLXProtalix BioTherapeutics Inc252.18M
ABEOAbeona Therapeutics Inc131.44M
RCKTRocket Pharmaceuticals Inc272.24M
LXEOLexeo Therapeutics Inc252.01M
DSGNDesign Therapeutics Inc689.67M
PASGPassage Bio Inc12.87M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ways Douglas KirkInterim Chief Medical OfficerDec 11 '25Option Exercise0.001,25001,250Jan 21 04:04 PM
Gharib Samir M.PRESIDENT AND CFODec 15 '25Option Exercise0.001,00908,447Dec 17 04:58 PM
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICERDec 15 '25Option Exercise0.002,676014,922Dec 17 04:56 PM
Gharib Samir M.PRESIDENT AND CFODec 11 '25Option Exercise0.001,90008,296Dec 12 07:05 PM
Gharib Samir M.PRESIDENT AND CFODec 10 '25Option Exercise0.0051406,580Dec 12 07:05 PM
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICERDec 11 '25Option Exercise0.004,950015,192Dec 12 07:03 PM
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICERDec 10 '25Option Exercise0.001,196010,670Dec 12 07:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 104

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-8.510-5.676-8.5100.000.009
2026Q22026-08-12-6.680-5.790-6.6760.000.008
2026Q12026-05-13-8.940-7.934-8.9400.000.005
2025Q42026-03-09-8.730-9.158-10.6750.000.004
2025Q32025-11-10-14.580-13.935-14.5840.000.002
2025Q22025-08-14-3.500-18.000-3.4970.000.001
2025Q12025-05-06---23.963---
2024Q32024-11-12---15.7460.60--
2024Q22024-08-12---16.7281.61--
2024Q12024-05-13---21.2152.00--
2023Q32023-11-13---22.7603.07--
2023Q22023-08-14---23.7202.17--
2023Q12023-05-15---30.0731.96--
2022Q32022-11-10---36.293---
2022Q22022-08-10---37.900---
2022Q12022-05-11---37.550---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-96.748-70.048-96.3954.905.09
2025FY-50.830-21.240-50.8300.000.00
2026FY--28.039--0.00
2027FY-1.618--78.72
2028FY--10.323--33.69
2029FY--3.698--68.78
2030FY-3.913--109.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-099000.000.000.00
2026Q4S2026-09-169000.000.000.00
2026Q4S2026-08-128000.000.000.00
2026Q4S2026-07-078000.000.000.00
2026Q4S2026-06-157000.000.000.00
2026Q4S2026-06-056000.000.000.00
2026Q4S2026-05-135000.000.000.00
2026Q4S2026-05-045000.000.000.00
2026Q4S2026-05-035010.000.000.00
2026Q4S2026-04-245020.000.000.00
2026Q4S2026-03-094020.000.000.00
2026Q4S2026-02-183020.000.000.00
2026Q4S2026-02-173013.600.0010.80
2026Q4S2026-02-043003.770.0010.80

Estimate history

EPS, annual-33.209-42.285-95.245-135.776-147.213-93.324-96.395-50.83-34.7987
Period20182019202020212022202320242025TTM
EPS, quarterly-15.746-42.719-23.963-3.497-14.584-10.675-8.94-6.676-8.509
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000010.0894.91100
Period20182019202020212022202320242025TTM
Sales, quarterly0.6020.6970000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.2970.310.310.3130.3150.5470.5631.3722.874
Period20182019202020212022202320242025MRQ
Shares, quarterly0.5510.5630.5630.5630.5631.3721.3722.7532.874
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.004.9110.090.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.630.020.050.070.430.380.100.010.00
Gross Profit-1.63-0.024.8710.02-0.43-0.38-0.10-0.01-0.00
Selling, General and Administrative Excl. Other61.9536.4961.0262.0146.8541.6929.3113.109.97
Research and Development41.9819.5246.4249.4335.1230.6323.8210.808.40
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-63.58-36.51-56.15-51.99-47.28-42.07-29.42-13.11-9.97
Interest Expense2.980.090.310.480.420.340.320.070.00
Unusual Expense3.143.500.000.000.000.000.000.00-
Net Income Before Taxes-67.15-38.97-53.04-47.92-46.18-42.29-29.54-13.09-9.86
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-67.15-38.97-53.04-47.92-46.18-42.29-29.54-13.09-9.86
Net Income From Continuing Operations-67.15-38.97-53.04-47.92-46.18-42.29-29.54-13.09-9.86
Net Income-67.15-38.97-53.04-47.92-46.18-42.29-29.54-13.09-9.86
EPS (Recurring)-23.02-47.63-96.39-93.32-147.21-135.78-95.24-42.28-33.21
EPS (Basic, Before Extraordinaries)-34.80-50.83-96.39-93.32-147.21-135.78-95.24-42.28-33.21
EPS (Diluted)-34.80-50.83-96.39-93.32-147.21-135.78-95.24-42.28-33.21
EBITDA-61.95-36.49-56.10-51.92-46.85-41.69-29.31-13.10-9.97
Non-Operating Income (Expense)2.551.143.424.561.520.120.200.080.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.352.575.354.623.633.960.760.200.10
Price To Sales Ratio--3.5311.18-----
Gross Margin--99.0699.31-----
Operating Margin---1,143.37-515.34-----
Net Margin---1,079.94-474.96-----
Shares Outstanding2.871.370.560.550.310.310.310.310.30
Market Capitalization134.12134.1217.74119.2825.86104.77565.46573.15-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.70
Cost of Goods Sold Incl. D&A0.740.630.250.010.000.010.010.01
Gross Profit-0.74-0.63-0.25-0.01-0.00-0.01-0.010.69
Selling, General and Administrative Excl. Other23.2415.8811.7311.108.232.6914.4924.76
Research and Development18.1312.167.584.105.01-0.4310.8421.46
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.98-16.51-11.99-11.10-8.23-2.69-14.49-24.07
Interest Expense1.201.100.670.010.020.030.040.06
Unusual Expense-0.36-0.610.094.020.10-0.460.000.00
Net Income Before Taxes-24.01-16.23-12.27-14.65-8.21-2.07-14.04-23.56
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-24.01-16.23-12.27-14.65-8.21-2.07-14.04-23.56
Net Income From Continuing Operations-24.01-16.23-12.27-14.65-8.21-2.07-14.04-23.56
Net Income-24.01-16.23-12.27-14.65-8.21-2.07-14.04-23.56
EPS (Recurring)-8.60-6.85-8.89-8.63-14.46-4.04-23.96-42.72
EPS (Basic, Before Extraordinaries)-8.51-6.68-8.94-10.67-14.58-3.50-23.96-42.72
EPS (Diluted)-8.51-6.68-8.94-10.67-14.58-3.50-23.96-42.72
EBITDA-23.24-15.88-11.73-11.10-8.23-2.69-14.49-24.07
Non-Operating Income (Expense)0.820.770.490.480.140.190.490.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.100.870.691.690.41-0.080.540.96
Price To Sales Ratio----7.232.474.383.54
Gross Margin-------98.71
Operating Margin--------3,453.95
Net Margin--------3,380.06
Shares Outstanding2.872.751.371.370.560.560.560.56
Market Capitalization134.12148.6289.6693.245.043.0612.2517.74

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments48.9138.7596.3479.2988.97157.153.924.11
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets3.215.455.844.322.933.250.730.66
Total Current Assets52.1144.21102.1883.6191.89160.404.654.77
Net Property, Plant & Equipment0.670.931.181.401.621.790.000.00
Total Investments and Advances0.040.040.040.0332.670.220.000.00
Long-Term Note Receivable---0.10----
Intangible Assets------0.000.00
Other Assets0.210.030.550.510.300.480.040.00
Total Assets53.0245.21103.9585.65126.49162.884.694.78
Short Term Debt Incl. Current Port. of LT Debt0.321.911.871.760.362.801.250.00
Accounts Payable0.941.293.331.432.823.631.882.30
Other Current Liabilities8.8312.0519.269.265.693.331.170.41
Total Current Liabilities10.0915.2524.4612.458.879.764.302.71
Long Term Debt0.420.862.744.556.173.583.190.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.280.240.160.070.120.020.00
Total Liabilities10.5116.3927.4417.1615.1213.467.522.71
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0027.8119.87
Common Equity42.5228.8276.5168.49111.37149.43-30.64-17.80
Total Shareholders Equity42.5228.8276.5168.49111.37149.43-2.822.07
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity42.5228.8276.5168.49111.37149.43-2.822.07
Total Liabilities & Stockholders Equity53.0245.21103.9585.65126.49162.884.694.78
Book Value Per Share30.9951.18139.85217.64355.56481.81-98.98-59.97
Tangible Book Value Per Share30.9951.18139.85217.64355.56481.81-98.98-59.97
Full-Time Employees82129271517--
Price to Book Ratio2.020.621.400.330.943.78-11.14-
Return on Assets-79.34-71.12-50.55-43.54-29.23-35.25-276.50-
Return on Equity-109.24-100.70-66.10-51.35-32.43-40.30--
Return on Invested Capital-90.76-178.69-60.47-63.23-35.98-19.31-3,546.88-476.23
Quick Ratio5.172.904.186.7210.3616.431.081.76
Current Ratio5.172.904.186.7210.3616.431.081.76

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-67.15-38.97-53.04-47.92-46.18-42.29-29.54-13.09-9.86
Depreciation1.630.020.050.070.430.380.100.010.00
Other Funds (Non Cash)7.786.345.604.222.944.080.760.200.10
Funds from Operations-57.75-32.60-47.39-43.63-42.81-37.83-28.68-12.88-9.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital6.68-0.72-8.5710.361.131.961.160.261.19
Cash from Operating Activities-51.07-33.33-55.96-33.27-41.68-35.88-27.52-12.62-8.57
Capital Expenditures-0.140.000.00-0.01-0.01-0.09-0.07-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.0055.7823.70-79.080.000.000.00
Purchase of Investments0.000.000.00-11.88-36.80-79.080.000.000.00
Sale Or Maturity of Investments0.000.000.0067.6760.500.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.140.000.0055.7823.69-79.17-0.07-0.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock120.4350.070.2551.07-0.200.42181.0312.430.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock120.4350.070.2551.07-0.200.42181.0312.430.00
Proceedsfrom Stock Options50.0650.060.0751.07-0.200.10180.9812.430.00
Issuance or Reduction of Debt, Net13.36-2.06-1.62-1.620.000.220.000.000.00
Change in Long Term Debt13.36-2.06-1.62-1.620.000.220.000.000.00
Issuance of Long Term Debt14.200.000.000.000.004.990.000.000.00
Reduction of Long Term Debt-0.84-2.06-1.62-1.620.00-4.770.000.000.00
Net Financing Active Other Cash Flow-5.55-4.53-0.25-0.31-0.040.000.000.000.00
Other Financing Activities Uses-5.55-4.53-0.25-0.31-0.040.000.000.000.00
Cash from Financing Activities128.2443.48-1.6249.14-0.240.64181.0312.430.00
Net Change in Cash77.0210.15-57.5971.64-18.23-114.40153.44-0.19-8.57
Free Cash Flow-51.21-33.33-55.96-33.28-41.69-35.97-27.59-12.62-8.57
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments87.6996.3054.0848.9110.6716.39
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.614.860.953.213.854.57
Total Current Assets90.30101.1555.0352.1114.5220.95
Net Property, Plant & Equipment0.450.520.590.670.730.80
Total Investments and Advances0.040.040.040.040.040.04
Other Assets1.161.140.500.210.030.03
Total Assets91.95102.8556.1753.0215.3121.82
Short Term Debt Incl. Current Port. of LT Debt4.342.841.330.320.851.24
Accounts Payable2.731.212.680.941.390.81
Other Current Liabilities11.636.927.788.837.196.01
Total Current Liabilities18.7110.9611.7810.099.438.06
Long Term Debt3.984.845.800.420.500.58
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.973.323.940.000.000.00
Total Liabilities25.6519.1221.5210.519.938.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity66.3083.7334.6542.525.3913.18
Total Shareholders Equity66.3083.7334.6542.525.3913.18
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity66.3083.7334.6542.525.3913.18
Total Liabilities & Stockholders Equity91.95102.8556.1753.0215.3121.82
Book Value Per Share23.0730.4225.2530.999.5623.41
Tangible Book Value Per Share23.0730.4225.2530.999.5623.41
Full-Time Employees-2214899
Price to Book Ratio2.022.142.119.110.380.23
Return on Assets-125.20-82.38-84.70-79.34-119.08-99.32
Return on Equity-187.35-105.98-148.85-109.24-167.93-133.62
Return on Invested Capital-34.16-18.32-30.33-34.11-139.52-15.02
Quick Ratio4.839.234.675.171.542.60
Current Ratio4.839.234.675.171.542.60

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-24.01-16.23-12.27-14.65-8.21-2.07
Depreciation0.740.630.250.010.000.01
Other Funds (Non Cash)0.820.330.855.780.58-0.47
Funds from Operations-22.45-15.27-11.16-8.86-7.62-2.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital8.69-6.852.432.412.31-6.30
Cash from Operating Activities-13.76-22.12-8.73-6.46-5.32-8.83
Capital Expenditures0.00-0.14-0.010.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.14-0.010.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.3669.000.0050.070.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.3669.000.0050.070.000.01
Proceedsfrom Stock Options0.000.000.0050.060.000.01
Issuance or Reduction of Debt, Net0.050.0014.15-0.84-0.41-0.41
Change in Long Term Debt0.050.0014.15-0.84-0.41-0.41
Issuance of Long Term Debt0.050.0014.150.000.000.00
Reduction of Long Term Debt0.000.000.00-0.84-0.41-0.41
Net Financing Active Other Cash Flow3.74-4.53-0.23-4.530.000.00
Other Financing Activities Uses3.74-4.53-0.23-4.530.000.00
Cash from Financing Activities5.1664.4713.9244.69-0.40-0.40
Net Change in Cash-8.6042.225.1738.24-5.72-9.23
Free Cash Flow-13.76-22.25-8.74-6.46-5.32-8.83

Revenue breakdown

Pharmaceutical Preparations2024: 4.91M
United States2024: 4.91M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.17%0.5M2.5M81.25K
2026-10-1520.80%0.5M2.5M78.41K
2026-09-3017.19%0.4M2.5M76.67K
2026-09-1516.58%0.4M2.5M79.34K
2026-08-3123.17%0.4M1.9M67.17K
2026-08-1416.06%0.4M2.5M64.42K
2026-07-3118.74%0.4M2.3M63.91K
2026-07-1518.16%0.4M2.3M76.14K
2026-06-3015.69%0.4M2.3M75.81K
2026-06-1511.47%0.3M2.3M63.21K
2026-05-2910.56%0.2M2.3M61.15K
2026-05-159.39%0.2M2.3M62.93K
2026-04-309.28%0.2M2.2M63.27K
2026-04-1516.12%0.2M1.1M45.66K
2026-03-3115.25%0.2M1.1M39.48K
2026-03-1312.19%0.1M1.1M38.89K
2026-02-2714.11%0.1M0.9M56.10K
2026-02-138.86%0.1M0.9M73.65K
2026-01-308.06%0.1M0.9M97.87K
2026-01-156.88%0.1M0.9M119.44K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-04SCHEDULE 13G/ASEC
2026-07-30SCHEDULE 13GSEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-293Initial statement of beneficial ownership of securities2026-07-27SEC
2026-07-27SCHEDULE 13GSEC
2026-07-278-KCurrent report2026-07-27SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-268-KCurrent report2026-05-21SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-07SCHEDULE 13G/ASEC
2026-04-28SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AIGH Capital Management LLC8.70%
ORBIMED ADVISORS LLC7.27%
BlackRock, Inc.6.82%
MILLENNIUM MANAGEMENT LLC5.85%
Ikarian Capital, LLC4.41%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
Alyeska Investment Group, L.P.2.97%
ADAR1 Capital Management, LLC2.46%
GEODE CAPITAL MANAGEMENT, LLC2.32%
Cable Car Capital, LP2.18%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.09%
iShares Russell 2000 ETF2.37%
VANGUARD EXTENDED MARKET INDEX FUND1.16%
Fidelity Small Cap Index Fund1.08%
iShares Russell 2000 Value ETF0.61%
VANGUARD RUSSELL 2000 INDEX FUND0.54%
Fidelity Extended Market Index Fund0.46%
iShares Micro-Cap ETF0.31%
Schwab Small-Cap Index Fund0.25%
iShares Russell 2000 Growth ETF0.23%

OakChart. SPRB. Cached 15 minutes.